Entacapone improves complex movement performance in patients with Parkinson's disease

Journal of Clinical Neuroscience

Volumn 14, Issue 5, 2007, Pages 424-428

  Müller, Thomas ^a   Erdmann, Christoph ^a   Muhlack, Siegfried ^a   Bremen, Dirk ^b   Przuntek, Horst ^a   Woitalla, Dirk ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b Orion Pharma GmbH   (Germany)

Author keywords

Complex movements; Entacapone; Parkinson's disease; Peg insertion

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOPAMINE RELEASE; DRUG METABOLISM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; OPEN STUDY; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; STANDARDIZATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CATECHOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NITRILES; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX;

EID: 33947364316     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2006.02.008     Document Type: Article

References (19)

1. Müller T., Schafer S., Kuhn W., et al. Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 27 (2000) 311-315
2. Müller T., Benz S., and Przuntek H. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can J Neurol Sci 29 (2002) 73-77
3. Przuntek H., Müller T., and Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 111 (2004) 201-216
4. Müller T., Kuhn W., Schulte T., et al. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 339 (2003) 25-28
5. Goetz C.G., LeWitt P.A., and Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 18 (2003) 1455-1458
6. van Hilten J.J., Hoff J.I., Middelkoop H.A., et al. The clinimetrics of hypokinesia in Parkinson's disease: subjective versus objective assessment. J Neural Transm Park Dis Dement Sect 8 (1994) 117-121
7. Pal PK, Lee CS, Samii A, et al. Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. 2001;7:305-309.
8. Wang Y., Chan G.L., Holden J.E., et al. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30 (1998) 56-61
9. Saft C., Andrich J., Meisel N.M., et al. Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol 250 (2003) 1469-1474
10. Müller T., and Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat Disord 8 (2002) 181-186
11. Fuente-Fernandez R., and Stoessl A.J. The placebo effect in Parkinson's disease. Trends Neurosci 25 (2002) 302-306
12. Fuente-Fernandez R., and Stoessl A.J. The biochemical bases of the placebo effect. Sci Eng Ethics 10 (2004) 143-150
13. Müller T., Voss B., Hellwig K., et al. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 18 (2004) 105-111
14. Hughes A.J., Daniel S.E., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
15. Nutt J.G., Lea E.S., Van Houten L., et al. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov Disord 15 (2000) 843-849
16. Olanow C.W., Kieburtz K., Stern M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 61 (2004) 1563-1568
17. Rinne U.K., Larsen J.P., Siden A., et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51 (1998) 1309-1314
18. Ruottinen H.M., and Rinne U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19 (1996) 222-233
19. Olanow C.W., and Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?. Neurology 62 (2004) S72-S81